CD15+LOX-1+ PMN-MDSC is a
potential biomarker for NSCLC diagnosis
To confirm the potential of
CD15+LOX-1+ PMN-MDSCs applied as a
diagnostic marker for NSCLC, we firstly measured levels of CEA,
CYFRA21-1 and CA125 in serum of NSCLC patients, and then analyzed their
correlation with CD15+LOX-1+PMN-MDSC frequency. Results showed that levels of serum tumor markers
including CEA (7.348±1.024 ng/mL) (P <0.0001), CYFRA21-1
(7.436±0.9677 ng/mL) (P <0.0001) and CA125 (61.09±6.703
U/mL) (P <0.0001) increased prominently in NSCLC
patients compared with those in healthy donors (CEA: 1.77±0.1359 ng/mL;
CYFRA21-1: 1.799±0.1045 ng/mL; CA125: 14.57±0.9361 U/mL) (Figure 2A). We
also found that CD15+LOX-1+ PMN-MDSC
proportion was positively correlated with levels of CEA (r=0.6831,P =0.0021) and CYFRA21-1 (r=0.6598, P <0.0001),
but not CA125 (r=0.2687, P =0.0592), in NSCLC patients (Figure
2B). Moreover, ROC curves of
CD15+LOX-1+ PMN-MDSC frequency and
tumor markers were analyzed. The results showed that AUC of PMN-MDSC
frequency, CEA, CYFRA21-1 and CA125 in the diagnosis of NSCLC were
0.9996 (95% CI: 0.9983-1.001), 0.8852 (95% CI: 0.8226-0.9478), 0.9205
(95% CI: 0.8670-0.9740) and 0.8209 (95% CI: 0.7404-0.9015),
respectively (Figure 2C). These results indicate that
CD15+LOX-1+ PMN-MDSC is a potential
biomarker for NSCLC diagnosis.